Diagnosis and management of radiation cholecystitis as a complication of Y90 radioembolization for hepatocellular carcinoma
Radiation induced cholecystitis is a known but rare complication of Yttrium90 (Y90) radioembolization of hepatic tumors due to nontarget embolization. Many documented cases of radiation induced cholecystitis have been treated with cholecystectomy, which is significant given the typical patient popul...
| Published in: | Radiology Case Reports |
|---|---|
| Main Authors: | Joe Khoury, DO, MBA, Brenden Li, BS, Joyce Zhu, BS, Trevor Lin, BS, Eusha Hasan, BA, Ashley Lamba, BS, Vaiva Gustainyte, DO, Hakob Kocharyan, MD, Christopher Yeisley, MD, Elias Salloum, MD, Altan Ahmed, MD, Craig Greben, MD, Mustafa Al-Roubaie, MD |
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-08-01
|
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1930043324003972 |
Similar Items
Cholecystitis after yttrium-90 resin microsphere radioembolization treatment: Clinical and pathologic findings
by: Sagun Parakh, et al.
Published: (2016-07-01)
by: Sagun Parakh, et al.
Published: (2016-07-01)
Radioembolization for hepatocellular carcinoma: what clinicians need to know
by: Jin Woo Choi, et al.
Published: (2022-03-01)
by: Jin Woo Choi, et al.
Published: (2022-03-01)
Radioembolization Treatment for Liver Cancer
by: Ezgi Başak ERDOĞAN, et al.
Published: (2016-04-01)
by: Ezgi Başak ERDOĞAN, et al.
Published: (2016-04-01)
Liver Radioembolization: a New Chapter in Russian Oncology
by: A. D. Kaprin, et al.
Published: (2019-12-01)
by: A. D. Kaprin, et al.
Published: (2019-12-01)
Ipilimumab and nivolumab plus radioembolization as salvage therapy for atezolizumab and bevacizumab refractory hepatocellular carcinoma resulting in complete pathologic response
by: Claudia R. Silver, BS, et al.
Published: (2024-11-01)
by: Claudia R. Silver, BS, et al.
Published: (2024-11-01)
Yttrium-90 Radioembolization for Hepatic Metastases Secondary to Thymic Malignancies: A Case Report
by: Gavin Yuan, BA, et al.
Published: (2025-05-01)
by: Gavin Yuan, BA, et al.
Published: (2025-05-01)
Radioembolization and the dynamic role of 90Y PET/CT
by: Alexander S Pasciak, et al.
Published: (2014-02-01)
by: Alexander S Pasciak, et al.
Published: (2014-02-01)
A Comparison of Techniques for 90Y PET/CT Image-Based Dosimetry following Radioembolization with Resin Microspheres
by: Alexander Samuel Pasciak, et al.
Published: (2014-05-01)
by: Alexander Samuel Pasciak, et al.
Published: (2014-05-01)
Trans-arterial 90yttrium radioembolization for patients with unresectable tumors originating from the biliary tree
by: Joost W. Wijlemans, et al.
Published: (2011-07-01)
by: Joost W. Wijlemans, et al.
Published: (2011-07-01)
A Clinical Trial of The Evaluation of Environmental Exposure in Yttrium 90 Radioembolization
by: Handan Tanyildizi, et al.
Published: (2018-12-01)
by: Handan Tanyildizi, et al.
Published: (2018-12-01)
Predictors of Hepatic Decompensation after Yttrium90 Transarterial Radioembolization—Optimizing Patient Selection
by: Amelia Wong, et al.
Published: (2024-08-01)
by: Amelia Wong, et al.
Published: (2024-08-01)
Single-Compartment Dose Prescriptions for Ablative <sup>90</sup>Y-Radioembolization Segmentectomy
by: Srinivas Cheenu Kappadath, et al.
Published: (2023-05-01)
by: Srinivas Cheenu Kappadath, et al.
Published: (2023-05-01)
Yttrium-90 radioembolization in patients with hepatocellular carcinoma who have previously received sorafenib
by: Nitesh eRana, et al.
Published: (2013-12-01)
by: Nitesh eRana, et al.
Published: (2013-12-01)
Software development for hepatopulmonary shunt estimation by gamma camera method in transarterial radioembolization
by: Ashish Jha Jha, et al.
Published: (2019-10-01)
by: Ashish Jha Jha, et al.
Published: (2019-10-01)
Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility
by: Qian Yu, et al.
Published: (2023-11-01)
by: Qian Yu, et al.
Published: (2023-11-01)
Radioembolization: Emerging Opportunities in the Era of Personalized Medicine
by: Cicero Matthew R Habito
Published: (2015-10-01)
by: Cicero Matthew R Habito
Published: (2015-10-01)
Yttrium-90 Radioembolization as the Major Treatment of Hepatocellular Carcinoma
by: Yu CY, et al.
Published: (2023-01-01)
by: Yu CY, et al.
Published: (2023-01-01)
Precision dosimetry in yttrium-90 radioembolization through CT imaging of radiopaque microspheres in a rabbit liver model
by: E. Courtney Henry, et al.
Published: (2022-03-01)
by: E. Courtney Henry, et al.
Published: (2022-03-01)
Yttrium-90 Radioembolization of Metastatic Adrenocortical Carcinoma to the Liver following Systemic Chemotherapy and Surgical Resection of the Primary Lesion
by: Nicholas Pigg, et al.
Published: (2020-02-01)
by: Nicholas Pigg, et al.
Published: (2020-02-01)
Outcomes of Y90 Radioembolization for Hepatocellular Carcinoma in Patients Previously Treated with Transarterial Embolization
by: Ken Zhao, et al.
Published: (2024-05-01)
by: Ken Zhao, et al.
Published: (2024-05-01)
Optimization of 99mTc-SPECT in the presence of 90Y for radioembolization
by: Camiel E.M. Kerckhaert, et al.
Published: (2025-09-01)
by: Camiel E.M. Kerckhaert, et al.
Published: (2025-09-01)
The Influence of Additional Treatments on the Survival of Patients Undergoing Transarterial Radioembolization (TARE)
by: Natale Quartuccio, et al.
Published: (2024-03-01)
by: Natale Quartuccio, et al.
Published: (2024-03-01)
Ablative radioembolization of hepatocellular carcinoma with total arterial supply originating from the superior adrenal artery achieved complete pathologic necrosis
by: Gonzalo Arotzarena, BS, et al.
Published: (2023-01-01)
by: Gonzalo Arotzarena, BS, et al.
Published: (2023-01-01)
Short-term changes of angiogenesis factors after transarterial radioembolization in hepatocellular carcinoma patients
by: Hüseyin Tuğsan Ballı, et al.
Published: (2023-09-01)
by: Hüseyin Tuğsan Ballı, et al.
Published: (2023-09-01)
Identifying key predictors of mortality and liver decompensation in hepatocellular carcinoma patients treated with transarterial radioembolization
by: Mohammad Arabi, et al.
Published: (2025-05-01)
by: Mohammad Arabi, et al.
Published: (2025-05-01)
Transarterial radioembolization versus chemoembolization for hepatocellular carcinoma: a meta-analysis
by: Wenxiao Lu, et al.
Published: (2025-01-01)
by: Wenxiao Lu, et al.
Published: (2025-01-01)
Rapid predictive dosimetry for radioembolization
by: Yung Hsiang Kao
Published: (2024-01-01)
by: Yung Hsiang Kao
Published: (2024-01-01)
Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases
by: Nicholas Fidelman, et al.
Published: (2022-12-01)
by: Nicholas Fidelman, et al.
Published: (2022-12-01)
90Y SPECT scatter estimation and voxel dosimetry in radioembolization using a unified deep learning framework
by: Yixuan Jia, et al.
Published: (2023-12-01)
by: Yixuan Jia, et al.
Published: (2023-12-01)
The Essential Role of Monte Carlo Simulations for Lung Dosimetry in Liver Radioembolization with <sup>90</sup>Y Microspheres
by: Edoardo d’Andrea, et al.
Published: (2024-08-01)
by: Edoardo d’Andrea, et al.
Published: (2024-08-01)
A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis
by: Zhongzhi Jia, et al.
Published: (2016-01-01)
by: Zhongzhi Jia, et al.
Published: (2016-01-01)
Chemorefractory liver metastasis from cervical cancer successfully treated with a combination of yttrium-90 and immunotherapy
by: Michael E. Nance, et al.
Published: (2020-08-01)
by: Michael E. Nance, et al.
Published: (2020-08-01)
Optimization of Y-90 Radioembolization Imaging for Post-Treatment Dosimetry on a Long Axial Field-of-View PET/CT Scanner
by: Pia M. Linder, et al.
Published: (2023-11-01)
by: Pia M. Linder, et al.
Published: (2023-11-01)
Correspondence to letter to the editor on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”
by: Moon Haeng Hur, et al.
Published: (2025-01-01)
by: Moon Haeng Hur, et al.
Published: (2025-01-01)
Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization
by: Yuna Kim, et al.
Published: (2021-02-01)
by: Yuna Kim, et al.
Published: (2021-02-01)
Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma
by: Alexander Villalobos, et al.
Published: (2023-11-01)
by: Alexander Villalobos, et al.
Published: (2023-11-01)
Advances in SPECT for Optimizing the Liver Tumors Radioembolization Using Yttrium-90 Microspheres
by: Hoda Roshan, et al.
Published: (2015-04-01)
by: Hoda Roshan, et al.
Published: (2015-04-01)
Complications of Radioembolization: Prevention and Management
by: Gyoung Min Kim
Published: (2025-07-01)
by: Gyoung Min Kim
Published: (2025-07-01)
Spontaneous Contralateral Adrenal Hemorrhage during Periduodenal Abscess Drain Placement
by: Eusha Hasan, et al.
Published: (2024-02-01)
by: Eusha Hasan, et al.
Published: (2024-02-01)
Transarterial Radioembolization of Hepatocellular Carcinoma, Liver-Dominant Hepatic Colorectal Cancer Metastases, and Cholangiocarcinoma Using Yttrium90 Microspheres: Eight-Year Single-Center Real-Life Experience
by: Julie Pellegrinelli, et al.
Published: (2021-01-01)
by: Julie Pellegrinelli, et al.
Published: (2021-01-01)
Similar Items
-
Cholecystitis after yttrium-90 resin microsphere radioembolization treatment: Clinical and pathologic findings
by: Sagun Parakh, et al.
Published: (2016-07-01) -
Radioembolization for hepatocellular carcinoma: what clinicians need to know
by: Jin Woo Choi, et al.
Published: (2022-03-01) -
Radioembolization Treatment for Liver Cancer
by: Ezgi Başak ERDOĞAN, et al.
Published: (2016-04-01) -
Liver Radioembolization: a New Chapter in Russian Oncology
by: A. D. Kaprin, et al.
Published: (2019-12-01) -
Ipilimumab and nivolumab plus radioembolization as salvage therapy for atezolizumab and bevacizumab refractory hepatocellular carcinoma resulting in complete pathologic response
by: Claudia R. Silver, BS, et al.
Published: (2024-11-01)
